Sildenafil

This drug is a landmark discovery, which consequently has become the definitive therapy for the treatment of erectile dysfunction (ED). Following the major breakthrough in the field of nitric oxide (NO)-physiology and pharmacology leading to sildenafil being marketed, the most current information is presented in this reference book, including ongoing research from several disparate groups about NO as endothelium-derived relaxing factor (EDRF) and also as a neurotransmitter for nerves innervating erectile tissue in mammals. The development of sildenafil as an oral phosphodiesterase-5 (PDE5) inhibitor drug for the treatment of ED resulted in one of the first products, which made its way successfully from basic NO research to routine clinical therapy. This volume addresses all fields of sildenafil application in both men and women. In a highly competitive research environment with a critical medical need for drug improvements the reader will learn more about clinical resistance to sildenafil treatment and the modalities to overcome the failure rates. The individual chapters cover clinical use, pharmacokinetics, pharmacodynamics, biochemistry, and cultural aspects. They are written by leading experts in their respective fields. Therefore, readers – whether professionals in the pharmaceutical industry, physicians treating ED, biochemists, chemists or pharmacologists – will find a detailed and up-to-date knowledge base about current research activities and an excellent overview for further research on this compound class and its cultural impact. Front Matter....Pages I-IX The discovery and development of Viagra® (sildenafil citrate)....Pages 1-13 Sildenafil, pharmacology of a highly selective PDE5 inhibitor....Pages 15-33 Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction....Pages 35-47 Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy....Pages 49-65 Neurologic erectile dysfunction....Pages 67-81 Therapy of erectile dysfunction (ED) with sildenafil improves quality of life (QoL) and partnership (QoP)....Pages 83-100 Erectile dysfunction, depression, and pharmacological treatments: biologic interactions....Pages 101-115 Potential role for the PDE5 inhibitor sildenafil in the treatment of female sexual dysfunction....Pages 117-127 Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases....Pages 129-142 Sildenafil and cardiovascular events — drug interactions....Pages 143-149 Cardiovascular safety of sildenafil in the treatment of erectile dysfunction....Pages 151-162 NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension....Pages 163-168 The phosphodiesterase V inhibitor low responder study (PILRS) in patients with erectile dysfunction — A rationale for a PDE5 inhibitor combination therapy....Pages 169-181 Extended clinical use of sildenafil in patients with IPP, prostatitis and infertility syndrome....Pages 183-186 The cultural impact of sildenafil....Pages 187-194 Back Matter....Pages 195-202